Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01602614 · ClinicalTrials.gov registry record
Evaluation of the Pharmacokinetics (PK) and Pharmacodymamics (PD) of Ganciclovir (GCV) in Premature Infants Receiving Treatment for Cytomegalorivus (CMV) Infection
A clinical trial, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- 18
- Enrollment target
NCT01602614 is a clinical trial that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 18 participants.
The verdict
NCT01602614 has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- 18 participants
- Enrollment target
Study Summary
This is a clinical sampling study, and no study drugs will be administered under this protocol. Premature infants who receive intravenous ganciclovir as part of clinical care will be eligible for participation in this study. Intravenous ganciclovir will not be provided under this protocol.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2013-04 |
| Est. Completion | 2019-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01602614
The ClinicalTrials.gov registry entry for NCT01602614 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01602614 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01602614 about?
NCT01602614 is a clinical study titled "Evaluation of the Pharmacokinetics (PK) and Pharmacodymamics (PD) of Ganciclovir (GCV) in Premature Infants Receiving Treatment for Cytomegalorivus (CMV) Infection". This is a clinical sampling study, and no study drugs will be administered under this protocol. Premature infants who receive intravenous ganciclovir as part of clinical care will be eligible for participation in this study. Intravenous ganciclovir will not be provided under this protocol.
What is the current status of trial NCT01602614?
This trial is currently completed. The enrollment target is 18 participants. The study started on 2013-04. Estimated completion is 2019-03.
Who is sponsoring clinical trial NCT01602614?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.